Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Maniadakis, Nikos ^a   Kourlaba, Georgia ^a   Mougiakos, Theodoros ^b   Chatzimanolis, Ioannis ^c   Jonsson, Linus ^d  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b Psychiatric Clinic   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d OptumInsight   (Sweden)

Author keywords

Agomelatine; Cost effectiveness; Cost utility; Depression; Greece

Indexed keywords

ACETAMIDE DERIVATIVE; AGOMELATINE; ANTIDEPRESSANT AGENT; GENERIC DRUG;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; GREECE; HUMAN; MAJOR DEPRESSION; MIDDLE AGED; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICS;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUGS, GENERIC; GREECE; HUMANS; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84877256517     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-173     Document Type: Article

References (42)

1. Cost of depression in Europe. Sobocki P, Jonsson B, Angst J, Rehnberg C, J Ment Health Policy Econ 2006 9 87 98 17007486 (Pubitemid 44018376)
2. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Wittchen HU, Jacobi F, Eur Neuropsychopharmacol 2005 15 357 376 10.1016/j.euroneuro.2005.04.012 15961293 (Pubitemid 40943541)
3. Depression in the community: the first pan-European study DEPRES (depression research in European society). Lepine JP, Gastpar M, Mendlewicz J, Tylee A, Int Clin Psychopharmacol 1997 12 19 29 10.1097/00004850-199701000-00003 9179630 (Pubitemid 27171192)
4. Severe depression: is there a best approach? Sonawalla SB, Fava M, CNS Drugs 2001 15 765 776 10.2165/00023210-200115100-00003 11602003 (Pubitemid 33065427)
5. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B, Int J Clin Pract 2006 60 791 798 16846399 (Pubitemid 43881154)
6. Friedman E, Anderson IM, Managing depression in clinical practice London: Springer 2010
7. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH, J Occup Environ Med 2008 50 428 436 10.1097/JOM.0b013e31816b5034 18404015 (Pubitemid 351521617)
8. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Kent JM, Lancet 2000 355 911 918 10.1016/S0140-6736(99)11381-3 10752718 (Pubitemid 30137678)
9. Physiological genomics of antidepressant targets: keeping the periphery in mind. Blakely RD, J Neurosci 2001 21 8319 8323 11606618 (Pubitemid 33051428)
10. Current trends in the development of new antidepressants. Pacher P, Kohegyi E, Kecskemeti V, Furst S, Curr Med Chem 2001 8 89 100 10.2174/0929867013373796 11172668 (Pubitemid 32409768)
11. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ, Nat Rev Drug Discov 2010 9 628 642 20577266
12. Agomelatine: the evidence for its place in the treatment of depression. Eser D, Baghai TC, Moller HJ, Core Evid 2009 4 171 179
13. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. Kennedy SH, Rizvi SJ, CNS Drugs 2010 24 479 499 10.2165/11534420-000000000-00000 20192279
14. Briggs A, Claxton K, Sculpher M, Decision modelling for health economic evaluation New York: Oxford University Press Inc 2006
15. Evidence of cost-effective treatments for depression: a systematic review. Barrett B, Byford S, Knapp M, J Affect Disord 2005 84 1 13 10.1016/j.jad.2004.10.003 15620380 (Pubitemid 40037775)
16. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Sobocki P, Ekman M, Ovanfors A, Khandker R, Jonsson B, Int J Clin Pract 2008 62 623 632 10.1111/j.1742-1241. 2008.01711.x 18284439 (Pubitemid 351348039)
17. Model to assess the cost-effectiveness of new treatments for depression. Sobocki P, Ekman M, Agren H, Jonsson B, Rehnberg C, Int J Technol Assess Health Care 2006 22 469 477 16984680 (Pubitemid 44622967)
18. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D, Hellenic J Cardiol 2005 46 212 221 15981557 (Pubitemid 41664057)
19. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association, Am J Psychiatry 2000 157 1 45 11085570
20. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Lemoine P, Guilleminault C, Alvarez E, J Clin Psychiatry 2007 68 1723 1732 10.4088/JCP.v68n1112 18052566 (Pubitemid 350247502)
21. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Bayle FJ, J Clin Psychiatry 2010 71 109 120 10.4088/JCP.09m05347blu 20193645
22. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V, Int Clin Psychopharmacol 2010 25 305 314 10.1097/YIC.0b013e32833a86aa 20856123
23. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, Guilleminault C, Int Clin Psychopharmacol 2011 26 252 262 10.1097/YIC.0b013e328349b117 21829106
24. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Bielski RJ, Ventura D, Chang CC, J Clin Psychiatry 2004 65 1190 1196 10.4088/JCP.v65n0906 15367045
25. Recurrence of bipolar disorders and major depression. A life-long perspective. Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H, Eur Arch Psychiatry Clin Neurosci 2003 253 236 240 10.1007/s00406-003-0437-2 14504992 (Pubitemid 37203960)
26. Suicide as an outcome for mental disorders. A meta-analysis. Harris EC, Barraclough B, Br J Psychiatry 1997 170 205 228 10.1192/bjp.170.3.205 9229027 (Pubitemid 27117683)
27. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I, Int Clin Psychopharmacol 2004 19 271 280 10.1097/01.yic.0000137184.64610.c8 15289700 (Pubitemid 39141943)
28. A study to determine the maintenance of efficacy of agomelatine (25 mg or 50 mg) in order to prevent relapses in out-patients with major depressive disorder. Rouillon F, A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period Créteil, France 2007
29. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Kennedy SH, Rizvi S, Fulton K, Rasmussen J, J Clin Psychopharmacol 2008 28 329 333 10.1097/JCP.0b013e318172b48c 18480691
30. Discontinuation symptoms in depression and anxiety disorders. Baldwin DS, Montgomery SA, Nil R, Lader M, Int J Neuropsychopharmacol 2007 10 73 84 10.1017/S1461145705006358 16359583 (Pubitemid 46122754)
31. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. Goodwin GM, Emsley R, Rembry S, Rouillon F, J Clin Psychiatry 2009 70 1128 1137 10.4088/JCP.08m04548 19689920
32. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Martensson B, Jonsson B, Value Health 2007 10 153 160 10.1111/j.1524-4733. 2006.00162.x 17391424 (Pubitemid 46481142)
33. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. Sullivan PW, Valuck R, Saseen J, MacFall HM, CNS Drugs 2004 18 911 932 10.2165/00023210-200418130- 00006 15521793 (Pubitemid 39612019)
34. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ, CNS Drugs 2007 21 319 334 10.2165/00023210-200721040-00005 17381185 (Pubitemid 46598451)
35. EPAR summary for the public. European Medicines Agency.s Valdoxan, 2012 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000915/WC500046224.pdf
36. Drug Price Bulletin. Greek Ministry of Healths, 2012 http://www.yyka.gov. gr/
37. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B, Value Health 2004 7 518 528 10.1111/j.1524-4733.2004.75003.x 15367247 (Pubitemid 39390832)
38. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Devlin N, Parkin D, Health Econ 2004 13 437 452 10.1002/hec.864 15127424 (Pubitemid 38660393)
39. Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health. World Health Organization, Book WHO commission on macroeconomics and health: macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health Geneva, Switzerland 2001 http://whqlibdoc.who.int/publications/2001/924154550x.pdf, accessed September 2012
40. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ, J Clin Oncol 2008 26 3995 4000 10.1200/JCO.2007.13.2662 18711190
41. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Lothgren M, Zethraeus N, Health Econ 2000 9 623 630 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V 11103928
42. Choice of treatment with antidepressants: influencing factors. Himmerich H, Wranik DW, Curr Pharm Des 2012 18 5958 5975 10.2174/138161212803523653 22681172